Hyperbranched cationic polymers as nucleic acid delivery vehicles for transfected cells

By developing highly branched cationic polymers, the reaction of four-branched monomers with diacrylate and amine components was solved, and the problem of insufficient transfection efficiency and cytocompatibility of existing vectors was achieved, achieving more efficient genes Treatment effects and better cell viability.

CN114630855BActive Publication Date: 2024-12-03NATIONAL UNIVERSITY OF IRELAND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080067031.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-09-25
Filing Date
2020-09-22
Publication Date
2024-12-03
Estimated Expiration
2040-09-22

AI Technical Summary

Technical Problem

Existing nonviral gene delivery vectors, such as cationic liposomes and linear poly(β-aminoesters), have insufficient transfection efficiency and cytocompatibility, resulting in limited clinical transformation of gene therapy, and safety and The stability problem has not been fully resolved.

Method used

A highly branched cationic polymer was developed, formed by reaction of four-branched monomers with diacrylate and amine components, increasing positive charge and functional terminal groups on the polymer, improving transfection efficiency and Cell compatibility in cells reduces endosomal escape.

Benefits of technology

The transfection efficiency and cell viability are significantly improved in different cell types, providing higher gene therapy effects, and improving the safety and stability of the vector.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114630855B_ABST
    Figure CN114630855B_ABST
Patent Text Reader

Abstract

Hyperbranched cationic polymers are described. The polymers use 4-branched monomers, and due to the additional branching units, the number of functional end groups is increased, thereby providing excellent transfection efficiency and cytocompatibility in different cell types (including aADSC, HeLa, Neu7 and RDEB keratinocytes), and providing different gene therapy methods, such as GFP plasmid DNA and ribonucleoprotein CRISP-Cas 9 complex for COL7A1 exon 80 skipping. In addition, the additional branching units of the polymers of the present invention increase the positive charge on the polymer, improving endosomal escape in cells. The 4-branching unit can be a diamine component or a tetraacrylate component, although other 4-branching monomers can be used, such as any component with a tetraacrylamide group (i.e., 4-arm PEG acrylamide, 4-arm PEG maleimide), any component with a tetra-N-hydroxysuccinimide (NHS) group (i.e., 4-arm PEG-succinimidyl carbonate NHS ester), any type of tetrathiol component (i.e., pentaerythritol tetrakis(3-mercaptopropionate), 4-arm PEG-thiol, tetrakis(2-mercaptoethyl)silane), and any tetraepoxy component (i.e., tetraglycidyl methylenedianiline, tetraglycidyl 1,1'-methylenebis(naphthalene-2,7-diol), pentaerythritol tetraglycidyl ether, 4-arm polyethylene glycol epoxide).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to hyperbranched polymers. Compositions comprising a hyperbranched polymer complexed with a nucleic acid are also envisaged, as well as the use of said compositions for transfecting cells. Background Art

[0002] After nearly three decades of development, gene therapy has become a major part of the rapidly growing nanomedicine program to improve health conditions and correct genetic conditions. Although multiple clinical trials have been conducted using viral gene delivery vectors, the risks of eliciting immunogenic responses and transgene insertional mutagenesis, limitations associated with large-scale production and low genetic material "cargo capacity", and unpredictable vector mobility remain unresolved. The only approved gene therapy in history is Glybera, a viral gene therapy for reversing lipoprotein lipase deficiency (LPDL). This therapy was approved by the EMA, but the FDA required additional long-term studies that uniQure was unable to complete. Due to the cost of 1 million per treatment, the product was ultimately not brought to market.

[0003] From this perspective, the prospects of non-viral gene delivery vectors will be better because they have very low immunogenicity, non-tumorigenicity, high cost-effectiveness, high nucleic acid load and potential for local gene expression. The most common non-viral methods include expensive physical methods such as gene guns, electroporation and injection as well as relatively inefficient and toxic chemical preparations. Transfection efficiency, for example, was only 27% and 44% for enhanced green fluorescent protein (EGFP) in human dermal fibroblasts and human primary fibroblasts, respectively, using different electroporation systems. The leading cationic lipid reagents TransFectin, Lipofectanmmine LTX and electroporation have maximum transfection efficiencies of 15.7%, 11.8% and 48.1% in mouse embryonic fibroblasts, respectively. Moreover, in addition to being expensive, those physical methods cannot be carried out in vivo and are limited to in vitro use, so their use is indeed limited.

[0004] Cationic lipid DNA complexes (lipoplexes) are the most commonly studied non-viral system, however, cationic polymer DNA complexes (polyplexes) have been found to be more stable. Cationic polymers are an attractive alternative due to their ease of synthesis, versatility and improved safety compared to viruses. Non-viral vectors can condense nucleic acids into nanoparticles through electrostatic interactions, protect them from enzymatic degradation, and facilitate transport across cell membranes in an efficient and cytocompatible manner. Clinical translation of polymer-based non-viral gene delivery systems has been limited so far due to low transfection efficiency and poor transgene expression. The first clinical trial using polymers for gene therapy dates back to 2010, when cyclodextrin was used to deliver siRNA for cancer treatment. Among polymer-based gene therapy options, some clinical trials, such as the readily available cationic polymer polyethyleneimine (PEI), have shown some promise. However, PEI cannot be degraded and is severely hampered by its safety issues. Since then, many polymer-based clinical trials, mainly using PEI derivatives, have not been conducted, and none have been approved by the FDA due to failure to meet their primary endpoints (Davis, 2009, Chen et al., 2016). Despite this apparent failure, it shows that the clinical translation of polymer-based gene therapy is just waiting for the development of effective delivery vehicles.

[0005] Linear poly(β-amino esters) (LPAEs) have become one of the most versatile gene delivery vectors. Since the initial development of LPAEs by Lynn and Langer in 2000, Green et al. and Anderson et al. have designed, synthesized, and screened more than 2,500 LPAEs. The best performing C32 series has been identified for in vitro and in vivo gene delivery, even comparable to adenoviral delivery in human umbilical vein endothelial cells. To date, most design, synthesis, and transfection studies of poly(β-amino esters) have focused on their linear structures. Although the results with LPAEs are very encouraging, the potential to synthesize and optimize structures with multiple functional groups is limited by the linear nature of these polymers.

[0006] WO2016 / 020474 describes the formation of highly branched poly(β-amino esters) by reacting a 3-branched triacrylate component, a diacrylate component, and a primary amine component together to form a polymer, and then reacting the polymer with a primary or secondary amine end-capping monomer to provide a highly branched cationic polymer. It was found that the gene transfection efficiency of such polymers was enhanced compared to linear poly(β-amino esters). US2017 / 209597 describes the use of at least one tetrafunctional nonionic amphiphilic block copolymer as a carrier for capped or uncapped mRNA for intracellular delivery of gene therapy. US2003 / 215395 describes a controllably degradable cationic polymer for delivering biomolecules (nucleic acids, peptides, etc.), drugs, molecules used in medical imaging applications, sensitizers used in cancer treatment, and molecules used in tissue engineering.

[0007] It is an object of the present invention to overcome at least one of the problems mentioned above. Summary of the invention

[0008] The applicant provides a highly branched cationic polymer, which uses a 4-branched monomer, and due to the additional branching unit, the number of functional terminal groups is increased, thereby providing excellent transfection efficiency and cell compatibility in different cell types (including aADSC, HeLa, Neu7 and RDEB keratinocytes), and providing different gene therapy methods, such as GFP plasmid DNA and ribonucleoprotein CRISP-Cas 9 complex for COL7A1 exon 80 skipping. In addition, the additional branching unit of the polymer of the present invention increases the positive charge on the polymer, improving intracellular endosomal escape. As described herein, the 4-branching unit can be a diamine component or a tetraacrylate component, although other 4-branching monomers can be used, such as any component having a tetraacrylamide group (i.e., 4-arm PEG acrylamide, 4-arm PEG maleimide), any component having a tetra-N-hydroxysuccinimide (NHS) group (i.e., 4-arm PEG-succinimidyl carbonate NHS ester), any type of tetrathiol component (i.e., pentaerythritol tetrakis(3-mercaptopropionate), 4-arm PEG-thiol, tetrakis(2-mercaptoethyl)silane), and any tetraepoxy component (i.e., tetraglycidyl methylenedianiline, tetraglycidyl 1,1'-methylenebis(naphthalene-2,7-diol), pentaerythritol tetraglycidyl ether, 4-arm polyethylene glycol epoxide).

[0009] In a first aspect, the present invention provides a polymer prepared by reacting together:

[0010] (i) a tetrabranched monomer having four reactive sites that can react with acrylate or amine groups;

[0011] (ii) a diacrylate component generally having formula (I),

[0012]

[0013] wherein Z2 is a straight or branched carbon chain of 1 to 30 carbon atoms, a straight or branched carbon chain of 1 to 30 atoms containing heteroatoms, a carbocyclic ring containing 3 to 30 carbon atoms, or a heterocyclic ring containing 3 to 30 atoms;

[0014] wherein Z2 is unsubstituted or substituted by at least one of halogen, hydroxyl, amino, sulfonyl, sulfonamide, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C5 alkyl, carboxyl, cyano, nitro, nitroso, -OC(0)NR'R', -N(R')C(0)NR'R, -N(R')C(0)0-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl;

[0015] (iii) a first amine component typically comprising 3 to 20 atoms,

[0016] wherein the amine component is typically unsubstituted or substituted with at least one of halogen, hydroxy, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C6 alkyl, carboxyl, cyano, nitro, nitroso, -OC(0)NR'R', -N(R')C(0)NR'R, -N(R')C(0)0-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl, and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl; and

[0017] (iv) a second amine component typically comprising 3 to 20 atoms,

[0018] The amine component is typically unsubstituted or substituted by at least one of halogen, hydroxy, amino, sulfonyl, sulfonamide, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C6 alkyl, carboxyl, cyano, nitro, nitroso, -OC(0)NR'R', -N(R')C(0)NR'R, -N(R')C(0)0-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl.

[0019] In another aspect, there is provided a method of forming a polymer, comprising the steps of reacting together:

[0020] (i) four-branched monomers;

[0021] (ii) a diacrylate component generally having formula (I),

[0022]

[0023] wherein Z2 is a straight or branched carbon chain of 1 to 30 carbon atoms, a straight or branched carbon chain of 1 to 30 atoms containing heteroatoms, a carbocyclic ring containing 3 to 30 carbon atoms, or a heterocyclic ring containing 3 to 30 atoms;

[0024] wherein Z2 is unsubstituted or substituted by at least one of halogen, hydroxy, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C5 alkyl, carboxyl, cyano, nitro, nitroso, -OC(0)NR'R', -N(R')C(0)NR'R, -N(R')C(0)0-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl;

[0025] (iii) a first amine component typically comprising 3 to 20 atoms,

[0026] wherein the amine component is typically unsubstituted or substituted with at least one of halogen, hydroxy, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C6 alkyl, carboxyl, cyano, nitro, nitroso, -OC(0)NR'R', -N(R')C(0)NR'R, -N(R')C(0)0-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl, and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl; and

[0027] (iv) a second amine component typically comprising 3 to 20 atoms,

[0028] The amine component is typically unsubstituted or substituted by at least one of halogen, hydroxy, amino, sulfonyl, sulfonamide, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C6 alkyl, carboxyl, cyano, nitro, nitroso, -OC(0)NR'R', -N(R')C(0)NR'R, -N(R')C(0)0-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl.

[0029] In one embodiment, a polymer is formed using an oligomer combination method, wherein a diacrylate and a first amine component react together to form a first oligomer, the first oligomer and a second amine component react together to form a second oligomer, and the second oligomer and a tetra-branched monomer react together to form a hyperbranched polymer of the present invention. Zeng et al. (Nano. Lett. 2019 19, 381-391) describe this oligomer combination method in detail.

[0030] In another embodiment, the tetra-branched monomer, the diacrylate component and the first amine component are reacted together in a Michael addition reaction to form a first polymer, and the first polymer and the second amine component (capped amine) are reacted together in a Michael addition reaction to form the hyperbranched polymer of the present invention.

[0031] In one embodiment, the tetra-branching monomer is selected from a diamine or a tetraacrylate component.

[0032] In one embodiment, the diamine component has a structure NH2-L4-NH2, wherein L4 is a linker. The linker can be an aryl or heteroaryl group, such as a C1-C10 aryl or heteroaryl group, including 0-5 heteroatoms selected from O, N and S.

[0033] In one embodiment, the diamine component is selected from:

[0034]

[0035] In one embodiment, the tetraacrylate component is a 4-arm PEG acrylate or has formula (II),

[0036]

[0037] Where Z1 is a bracket, including:

[0038] A straight or branched carbon chain of 1 to 30 carbon atoms, a straight or branched carbon chain of 1 to 30 atoms containing heteroatoms, a carbocyclic ring containing 3 to 30 carbon atoms, or a heterocyclic ring containing 3 to 30 atoms;

[0039] wherein Z1 is unsubstituted or substituted by at least one of halogen, hydroxy, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C6 alkyl, carboxyl, cyano, nitro, nitroso, -OC(0)NR'R', -N(R')C(0)NR'R, -N(R')C(0)0-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl;

[0040] In one embodiment, the tetraacrylate component is selected from:

[0041]

[0042] In one embodiment, the diacrylate component of formula (I) is selected from:

[0043]

[0044] In one embodiment, the first amine component is selected from:

[0045] In one embodiment, the second amine component is a diamine component having the structure NH2-L4-NH2 or is selected from:

[0046] In a preferred embodiment, the second amine component is selected from:

[0047]

[0048] In another aspect, there is provided a composition comprising the hyperbranched polymer of the present invention.

[0049] In one embodiment, the composition is a pharmaceutical composition and comprises a pharmaceutically acceptable excipient.

[0050] In one embodiment, the composition comprises a nucleic acid component complexed with a polymer of the present invention. The composition is referred to herein as a "polyplex". The nucleic acid component can be a complex of a nucleic acid, a nucleic acid and a protein / peptide or a combination of a protein or peptide (ribonucleoprotein). In one embodiment, the nucleic acid component is a nucleic acid, a gene editing system, a plasmid, a microcircle, a nanoplasmid or an expression vector. The nucleic acid can be DNA, RNA or a combination of the two. RNA can be used in the form of, including but not limited to, siRNA, dsRNA, shRNA, microRNA, crRNA, tracRNA, sgRNA, mRNA, RNA oligonucleotides, antisense oligonucleotides. The gene editing system can be a CRISPR-associated Cas system (Sander and Joung (2014) CRISPR-Cas systems for editing, regulating and targeting genomes Nature Biotechnology 32 (4): 347-355)), a TALEN system (Boch J (February 2011); "TALEs of genome targeting". Nature Biotechnology. 29 (2): 135–6. doi: 10.1038 / nbt.1767. PMID 21301438), a large-range nuclease system or a zinc finger nuclease (ZFN) system (Carroll, D (2011) "Genome engineering with zinc-finger nucleases". Genetics Society of America. 188 (4): 77378 doi: 10.1534 / genetics. 111.131433. PMC 3176093. PMID 21828278).In one embodiment, the gene editing system is configured to perform insertion mutagenesis on the cell, such as the OBLIGARE system and the CRISPR-Cpf1 system (Maresca et al. (2013) Obligate Ligation-Gated Recombination (ObLiGaRe): Custom-designed nuclease-mediated targeted integration through nonhomologous endjoining Genome Res. 23:539-546; see also WO 2014 / 033644), Fagerlund et al. (2015) The Cpf1 CRISPR-Cas protein expands genome-editing tools Genome Biology 16:251-253; Ledford (2015) Bacteria yield new gene cutter Smaller CRISPR enzyme should simplify genome editing Nature 526:17).

[0051] In one embodiment, the composition is in the form of particles. In one embodiment, the particle size of the particle composition is less than 2 μm, 1.5 μm, 1000 nm, such as 20-900 nm, 50-800 nm, 50-700 nm, 50-600 nm, 50-500 nm, 50-400 nm, 50-300 nm, 100-300 nm.

[0052] The compositions of the present invention can be used for gene addition, gene replacement, gene knockdown and gene editing. Gene replacement is defined as providing a functionally healthy gene copy to replace a dysfunctional mutant containing a pathogenic gene. Gene addition is defined as a therapeutic gene that supplements a specific aspect of the targeted disease mechanism. Gene knockdown is defined as a process that inhibits the ability of a target gene to synthesize toxic / dysfunctional proteins that cause disease. Gene editing is defined as a process that changes the nucleotide sequence of a target gene, thereby causing loss of function / correction / manipulation of gene expression. The gene editing system includes, but is not limited to, i) clustered regularly interspaced palindromic repeats (CRISPR)-associated (Cas) systems; (ii) transcription activator-like effector nuclease (TALEN) systems; or (iii) zinc finger nuclease (ZFN) systems.

[0053] Other applications include:

[0054] 1.) Research vector

[0055] 2.) If combined with a probe, the present invention can be used as a cell / tissue marker for research or diagnosis

[0056] 3.) If combined with pharmaceutical agents, it can be used as a drug delivery system

[0057] 4.) Can be used to target specific cell types if combined with a targeting moiety

[0058] 5.) If combined with pharmaceutical agents and targeting moieties, they can be used to deliver drugs in specific organs, tissues or cell types.

[0059] In another aspect, a method for transfecting cells is provided, comprising the step of contacting one or more target cells with a composition of the invention under conditions suitable for transfecting the cells with the composition. The transfection may be in vivo, ex vivo or in vitro. The transfection may involve modifying the genome of the cell (e.g., by deleting all or part of the genome), inserting sequences into the genome (insertional mutagenesis), silencing genes, replacing genes, upregulating gene expression, editing the genome (e.g., deleting disease-causing mutations), and adding residues required for the normal functioning of genes.

[0060] In another aspect, the invention relates to a cell transformed using the method of the invention.

[0061] Further aspects and preferred embodiments of the invention are defined and described in the further claims listed below. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] Figure 1 The polymer chain growth of Y4 hyperbranched polymer during Michael addition polymerization is shown. The monomer content decreases as the polymer chain grows.

[0063] Figure 2 The purified GPC results of Y4 hyperbranched polymer after 48 hours of end-capping reaction are shown.

[0064] Figure 3 The NMR spectrum of the purified hyperbranched Y4 polymer is shown. No acrylate peaks remain, which means that all terminal acrylate groups are converted to amine-terminated groups.

[0065] Figure 4 It was shown that after transfection of different cell lines (rADSC, HeLa and Neu7) with gWIZ plasmid at polymer / DNA ratios of 30:1 and 60:1, Y4 polymers with different branching ratios and different Mw induced higher cell viability than commercial transfection vectors (SuperFect, FuGene and PEI), and the cell viability was determined by AlamarBlue.

[0066] Figure 5The results showed that compared with the commercial PEI transfection vector, the polyplexes formed by Y4 polymer (with different end-capping monomers) and gWIZ plasmid at ratios of 30:1 and 60:1 induced higher transfection efficiency, which was measured by the luciferase activity after transfection of rADSC and Neu7 cell lines.

[0067] Figure 6 It shows that compared with the commercial transfection vectors FuGene, SuperFect, PEI and XFect, Y4 polymers with different branching ratios and Mw (samples 15, 17, 25, 27) have higher GFP-labeled fluorescence emission and higher transfection efficiency after transfection with gWIZ plasmid.

[0068] FIG. 7 shows the P1, P2 and P3 polymer chain growth during Michael addition polymerization.

[0069] FIG. 8 shows the GPC results of the purification of the polymers P1, P2 and P3 after 48 hours of end-capping reaction.

[0070] The NMR spectra of the purified P1, P2 and P3 polymers are shown in Figure 9. No acrylate peaks remain, which means that all terminal acrylate groups are converted to amine-terminated groups.

[0071] Fig.10 Comparison of the correction efficiency using the RNP system showed that the correction efficiency of the polyplexes using the hyperbranched polymers of the present invention (Y4 and P2) was higher than that of the HPAE polymers.

[0072] Figure 11 Proton nuclear magnetic resonance (1H-NMR) measurement of the four-branched polymer of the present invention:

[0073] (A) Y polymer-BDA-S5-EDA-103; (B) Y polymer-BDA-S5-EDA-122; (C) Y polymer-BDA-S5-HMDA-103; (D) Y polymer-BDA-S5-HMDA-122; (E) P polymer-BDA-S5-PTTA-103; (F) P polymer-BDA-S5-PTTA-122; (G) P polymer-BDA-S5-DTTA-103; (H) P polymer-BDA-S5-DTTA-122

[0074] FIG12 shows the molecular weight of the four-branched polymer of the present invention measured by gel permeation chromatography (GPC):

[0075] (A) Y polymer-BDA-S5-EDA-103; (B) Y polymer-BDA-S5-EDA-122; (C) Y polymer-BDA-S5-HMDA-103; (D) Y polymer-BDA-S5-HMDA-122; (E) P polymer-BDA-S5-PTTA-103; (F) P polymer-BDA-S5-PTTA-122; (G) P polymer-BDA-S5-DTTA-103; (H) P polymer-BDA-S5-DTTA-122. DETAILED DESCRIPTION

[0076] All publications, patents, patent applications, and other references mentioned herein are incorporated by reference in their entirety into this application for all purposes to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

[0077] Definition and general preferences

[0078] Unless otherwise specifically stated, the following terms used herein are intended to have the following meanings, in addition to any broader (or narrower) meanings they may have in the art:

[0079] Unless the context requires otherwise, the singular as used herein shall be understood to include the plural, and vice versa. The terms "a" or "an" used in relation to an entity shall be understood to refer to one or more of that entity. Thus, the terms "a" (or "an"), "one or more" and "at least one" are used interchangeably herein.

[0080] As used herein, the term "comprise" or variations thereof, such as "comprise" or "comprising", should be understood to include any listed integers (e.g., features, elements, characteristics, properties, method / process steps, or limitations) or groups of integers (e.g., features, elements, characteristics, properties, method / process steps, or limitations), but not to exclude any other integers or groups of integers. Thus, as used herein, the term "comprising" is inclusive or open-ended, and does not exclude additional, unlisted integers or method / process steps.

[0081] As used herein, the term "disease" is used to define any abnormal condition that impairs physiological function and is associated with specific symptoms. The term is used to broadly include any condition, illness, abnormality, pathology, illness, condition or syndrome in which physiological function is impaired, regardless of the nature of the cause (or whether the etiological basis of the disease is actually determined). Thus, it includes conditions caused by infection, trauma, injury, surgery, radiation ablation, aging, poisoning or nutritional deficiency.

[0082] As used herein, the term "treatment" or "treating" refers to an intervention (e.g., administration of a medicament to a subject) that cures, improves or alleviates disease symptoms or eliminates its cause (or alleviates its effects) (e.g., reduces the accumulation of pathological levels of lysosomal enzymes). In this case, the term is used synonymously with the term "therapy".

[0083] In addition, the term "treatment" or "treating" refers to an intervention (e.g., administering a pharmaceutical agent to a subject) that prevents or delays the onset or progression of a disease or reduces (or eradicates) its incidence in a treated population. In this case, the term treatment is used synonymously with the term "prevention."

[0084] As used herein, an effective dose or therapeutically effective dose of a medicament defines a dose that can be administered to a subject without excessive toxicity, irritation, allergic reaction or other problems or complications, commensurate with a reasonable benefit / risk ratio, but sufficient to provide the desired effect (e.g., a permanent or temporary improvement in the subject's condition to demonstrate treatment or prevention). The dose varies from subject to subject, depending on the age and general condition of the individual, the mode of administration and other factors. Therefore, although it is impossible to specify an accurate effective dose, a person skilled in the art will be able to determine the "effective" dose suitable for any individual using routine experiments and background common sense. The therapeutic results herein include the elimination or alleviation of symptoms, alleviation of pain or discomfort, prolonged survival, improved mobility and other signs of clinical improvement. The therapeutic result is not necessarily a complete cure. Improvement can be observed in terms of biological / molecular markers, clinical or observational improvements. In a preferred embodiment, the method of the present invention is applicable to humans, large racing animals (horses, camels, dogs) and domestic companion animals (cats and dogs).

[0085] In the context of treatment and effective doses as defined above, the term "subject" (which will be understood to include "individual," "animal," "patient," or "mammal" where the context permits) defines any subject, particularly a mammalian subject, for which treatment is to be given. Mammalian subjects include, but are not limited to, humans, livestock, farm animals, zoo animals, sports animals, pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, camels, bison, cattle, cows; primates, such as apes, monkeys, gorillas, and chimpanzees; canines, such as dogs and wolves; felines, such as cats, lions, and tigers; equines, such as horses, donkeys, zebras, etc.; food animals, such as cattle, pigs, and sheep; ungulates, such as deer and giraffes; and rodents, such as mice, rats, hamsters, and guinea pigs. In a preferred embodiment, the subject is a human. As used herein, the term "equine" refers to equine mammals, including horses, donkeys, asses, Tibetan wild asses, and zebras.

[0086] "Tetrabranched monomers" refers to components having a central four-branched scaffold and four reactive groups capable of reacting with acrylate or amine groups. Examples of tetrabranched monomers include diamine and tetraacrylate components, examples of which are provided above. The scaffold may also be a 4-arm PEG component, a pentaerythritol group, a tetraglycidyl group, or a tetrasubstituted silane group. The reactive groups may be any acrylamide component (including maleimide), N-hydroxysuccinimide (NHS) component, a thiol component, and an epoxy component. The following are specific examples of tetrabranched monomers that may be used in the processes and products of the present invention:

[0087] 4-Arm PEG Acrylamide

[0088]

[0089] 4-ArmPEG-Maleimide

[0090] 4-ArmPEG-Succinimidyl Carbonate NHS

[0091]

[0092] Tetrathiol component

[0093] Pentaerythritol tetrakis(3-mercaptopropionate):

[0094]

[0095] 4-Arm PEG-Thiol:

[0096]

[0097] Tetrakis(2-mercaptoethyl)silane:

[0098]

[0099] Tetraepoxy Component

[0100] Tetraglycidyl methylene dianiline:

[0101]

[0102] Tetraglycidyl 1,1'-methylenebis(naphthalene-2,7-diol):

[0103]

[0104] Pentaerythritol tetraglycidyl ether:

[0105]

[0106] 4-Arm Polyethylene Glycol Epoxide

[0107]

[0108] "Linker" refers to any linker group, including aryl or alkyl. Preferred linkers include O, NH, CH2, alkyl, lower alkyl, alkoxy, lower alkoxy, O-alkyl, CH2O, CH2NH and CH2NHCOCH2, CO, COO.

[0109] "Diamine component" refers to a moiety having two functional NH2 groups connected by a linker. "Tetraacrylate" refers to a moiety having four acrylate functional groups.

[0110] "Lower alkyl" refers to an alkyl group as defined below, but having 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms in its backbone structure (eg, "C-C-alkyl").

[0111] "Alkyl" refers to a group containing 1 to 8 carbon atoms, which can be a straight chain or branched chain group. An alkyl group is an optionally substituted straight chain, branched or cyclic saturated hydrocarbon group. When substituted, the alkyl group can be substituted by no more than four substituents at any available point of attachment. When an alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl". Exemplary unsubstituted such groups include methyl, ethyl, propyl, isopropyl, α-butyl, isobutyl, pentyl, hexyl, isohexyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, etc. Exemplary substituents may include, but are not limited to, one or more of the following groups: halogen (e.g., F, Cl, Br, I), haloalkyl (e.g., CCl or CF), alkoxy, alkylthio, hydroxy, carboxyl (-COOH), alkoxycarbonyl (-C(O)R), alkylcarbonyloxy (-OCOR), amino (-NH), carbamoyl (-NHCOOR- or -OCONHR), urea (-NHCONHR-), or thiol (-SH). The defined alkyl may also contain one or more carbon double bonds or one or more carbon-carbon triple bonds.

[0112] "Lower alkoxy" refers to an O-alkyl group, wherein alkyl is as defined above. The alkoxy group is bonded to the core compound via an oxygen bridge. The alkoxy group may be straight or branched; although straight chains are preferred. Examples include methoxy, ethoxy, propoxy, butoxy, tert-butoxy, isopropoxy, and the like. Preferably, the alkoxy group contains 1 to 4 carbon atoms, and particularly preferably, the alkoxy group contains 1 to 3 carbon atoms. Most preferably, the alkoxy group is methoxy.

[0113] "Halogen" refers to the non-metallic elements of Group 17 of the periodic table, namely bromine, chlorine, fluorine, iodine and astatine.

[0114] The terms "alkyl", "cycloalkyl", "heterocycloalkyl", "cycloalkylalkyl", "aryl", "acyl", "aromatic polycycle", "heteroaryl", "aralkyl", "heteroaralkyl", "aminoacyl", "non-aromatic polycycle", "mixed aromatic and non-aromatic polycycle", "polyheteroaryl", "non-aromatic polyheterocycle", "mixed aromatic and non-aromatic polyheterocycle", "amino" and "sulfonyl" are defined in U.S. Pat. No. 6,552,065 at column 4, line 52 to column 7, line 39.

[0115] "Halogen" refers to the non-metallic elements of Group 17 of the periodic table, namely bromine, chlorine, fluorine, iodine and astatine.

[0116] Gene therapy / editing

[0117] The present invention can be used to edit a portion of a cell's genome in a targeted and specific manner or to replace a portion of a cell's genome with an exogenous DNA insert.

[0118] Therefore, the present invention can be used to edit or replace defective parts of disease-causing genes (i.e., for gene repair), or to insert and inactivate (i.e., silence) genes whose expression is associated with the disease, or to edit or modify genes, such as deleting disease-causing mutations or modifying or adding residues required for the normal functioning of the gene.

[0119] The present invention therefore finds application in gene therapy as defined herein.

[0120] Gene therapy according to the present invention may target all cells in an organism, or may target a subpopulation of cells (eg, to selected organs, tissues or cells).

[0121] The gene therapy according to the present invention can specifically target somatic cells.

[0122] Gene therapy according to the present invention may exclude targeting germ cells. It may exclude targeting totipotent cells. It may exclude targeting human embryos.

[0123] Where the gene therapy according to the invention is applied to selected organs, tissues or cells, the method may be applied ex vivo to isolated organs, tissues or cells (e.g., blood, blood cells, immune cells, bone marrow cells, skin cells, nerve tissue, muscle, etc.).

[0124] Gene therapy can be used to treat any genetic disorder, especially those caused by a single gene mutation. Therefore, gene therapy has particular application in the treatment of lysosomal storage diseases, muscular dystrophy, cystic fibrosis, Marfan syndrome, sickle cell anemia, dwarfism, phenylketonuria, neurofibromatosis, Huntington's disease, osteogenesis imperfecta, thalassemia, and hemochromatosis.

[0125] Other diseases that may be suitable for gene therapy according to the present invention include: diseases and disorders of the blood, coagulation, heterogeneous skin diseases, cell proliferation and disorders, neoplasia (including cancer), inflammatory processes, the immune system (including autoimmune diseases), metabolism, liver, kidney, musculoskeletal, nervous, neuronal and ocular tissues.

[0126] Exemplary skin diseases include recessive dystrophic epidermolysis bullosa (RDEB), a rare, heterogeneous skin disease caused by biallelic loss-of-function mutations in the COL7A1 gene.

[0127] Exemplary blood and coagulation diseases and disorders include: anemia, bare lymphocyte syndrome, bleeding disorders, factor H, factor H-like 1, factor V, factor VIII, factor VII, factor X, factor XI, factor XII, factor XIIIA, factor XIIIB deficiency, Fanconi anemia, hemophagocytic lymphocytosis, hemophilia A, hemophilia B, bleeding disorders, leukocytosis, sickle cell anemia, and thalassemia.

[0128] Examples of immune-related diseases and conditions include: AIDS; autoimmune lymphoproliferative syndrome; combined immunodeficiency; HIV-1; HIV susceptibility or infection; immunodeficiency and severe combined immunodeficiency (SCLD). Autoimmune diseases that can be treated by the present invention include Graves' disease, rheumatoid arthritis, Hashimoto's thyroiditis, vitiligo, type I (early-onset) diabetes, pernicious anemia, multiple sclerosis, glomerulonephritis, systemic lupus erythematosus (SLE, lupus) and Sjögren's syndrome. Other autoimmune diseases include scleroderma, psoriasis, ankylosing spondylitis, myasthenia gravis, pemphigus, polymyositis, dermatomyositis, uveitis, Guillain-Barre syndrome, Crohn's disease and ulcerative colitis (commonly referred to as inflammatory bowel disease (IBD)).

[0129] Other exemplary diseases include: amyloid neuropathy; amyloidosis; cystic fibrosis; lysosomal storage disease; hepatic adenoma; liver failure; nervous system disorder; hepatic lipase deficiency; hepatoblastoma, cancer or carcinoma; medullary cystic kidney disease; phenylketonuria; polycystic kidney disease; or liver disease.

[0130] Exemplary musculoskeletal diseases and disorders include: muscular dystrophy (eg, Duchenne and Becker muscular dystrophy), osteoporosis, and muscular dystrophy.

[0131] Exemplary neural and neuronal diseases and disorders include: ALS, Alzheimer's disease; autism; fragile X syndrome, Huntington's disease, Parkinson's disease, schizophrenia, secretase-related disorders, trinucleotide repeat disorders, Kennedy's disease, Friedrich's ataxia, Machado-Joseph disease, spinocerebellar ataxia, myotonic dystrophy, and dentatorubral pallial atrophy with Lewy bodies (DRPLA).

[0132] Exemplary ocular diseases include: age-related macular degeneration, corneal opacities and dystrophies, congenital flat cornea, glaucoma, Leber congenital amaurosis, and macular dystrophy.

[0133] The gene therapy according to the present invention is particularly suitable for treating lysosomal storage diseases. Exemplary lysosomal storage diseases and corresponding defective enzymes are listed below:

[0134] Pompe disease: Acid alpha-glucosidase

[0135] Gaucher disease: Acid beta-glucosidase or glucocerebrosidase

[0136] Fabry disease: alpha-galactosidase A

[0137] GMI - Gangliosidosis: Acid beta-galactosidase

[0138] Tay-Sachs disease: β-hexosaminidase A

[0139] Sandhoff disease: β-hexosaminidase B

[0140] Niemann-Pick disease: Acid sphingomyelinase

[0141] Krabbe disease: Galactocerebrosidase

[0142] Farber disease: Acid ceramidase

[0143] Metachromatic leukodystrophy: Arylsulfatase A

[0144] Hurler-Scheie disease: alpha-L-iduronidase

[0145] Hunter disease: Iduronate-2-sulfatase

[0146] Sanfilippo disease A: Heparan N-sulfatase

[0147] Sanfilippo disease B: α-N-acetylglucosaminidase

[0148] Sanfilippo disease C: Acetyl-CoA: alpha-aminoglucosidase N-acetyltransferase

[0149] Sanfilippo disease D: N-acetylglucosamine-6-sulfate sulfatase

[0150] Morquio disease A: N-acetylgalactosamine-6-sulfate sulfatase

[0151] Morquio disease B: Acid beta-galactosidase

[0152] Maroteaux-Lamy disease: Arylsulfatase B

[0153] Sly disease: β-glucuronidase

[0154] Alpha-mannosidosis: Acid alpha-mannosidase

[0155] β-Mannosidosis: Acid β-mannosidase

[0156] Fucosidosis: Acid alpha-L-fucosidase

[0157] Sialidosis: Sialidase

[0158] Schindler-Kanzaki disease: alpha-N-acetylgalactosaminidase

[0159] Gene therapy according to the present invention is also particularly suitable for treating proteostatic diseases, including aggregation and misfolding proteostatic diseases, such as prion diseases, various amyloidoses and neurodegenerative diseases (such as Parkinson's disease, Alzheimer's disease and Huntington's disease), certain forms of diabetes, emphysema, cancer and cystic fibrosis.

[0160] Gene therapy according to the invention is particularly useful for treating cystic fibrosis, which occurs when a mutation in the CFTR gene results in reduced ion channel activity (through increased clearance of misfolded CFTR protein).

[0161] Gene therapy according to the present invention is particularly suitable for treating amplified CAG repeat sequence diseases. These diseases originate from the amplification of CAG repeat sequences of specific genes, in which the encoded protein has a corresponding polyglutamine bundle, resulting in aggregation and accumulation in the nucleus and cytoplasm of neurons. The aggregated amino-terminal fragments of mutant huntingtin protein are toxic to neuronal cells and are believed to mediate neurodegeneration. Examples include Huntington's disease (HD), which is characterized by selective neuronal cell death mainly in the cortex and striatum. CAG expansion has also been found in at least seven other hereditary neurodegenerative disorders, including, for example, spinal and bulbar muscular atrophy (SBMA), Kennedy disease, some forms of amyotrophic lateral sclerosis (ALS), dentate nucleus red nucleus pallidum Lewy body atrophy (DRPLA) and 1, 2, 3, 6 and 7 types of spinocerebellar ataxia (SCA).

[0162] Gene therapy according to the present invention is particularly suitable for treating any neoplasia, including proliferative diseases, benign, precancerous and malignant neoplasia, hyperplasia, metaplasia and dysplasia. Therefore, the present invention can be used to treat proliferative diseases, including but not limited to cancer, cancer metastasis, smooth muscle cell proliferation, systemic sclerosis, liver cirrhosis, adult respiratory distress syndrome, idiopathic cardiomyopathy, lupus erythematosus, retinopathy (such as diabetic retinopathy), cardiac hyperplasia, benign prostatic hyperplasia, ovarian cysts, pulmonary fibrosis, endometriosis, fibromatosis, hamartoma, lymphangiomatosis, sarcoidosis and desmoid tumor. The neoplasia related to smooth muscle cell proliferation includes excessive proliferation of cells in the vascular system (such as intimal smooth muscle cell hyperplasia, restenosis and vascular occlusion, especially including biological or mechanically mediated vascular injury (such as angioplasty) after stenosis). In addition, intimal smooth muscle cell hyperplasia may include smooth muscle hyperplasia (for example, obstruction of bile duct, bronchial airway and kidney in patients with renal interstitial fibrosis) except the vascular system. Non-cancerous proliferative disorders also include hyperproliferation of skin cells (e.g., psoriasis and its various clinical forms), Reiter's syndrome, pityriasis rubra pilaris, and various hyperproliferative forms of keratosis (including actinic keratosis, senile keratosis, and scleroderma). Particularly preferred is the treatment of malignant neoplasia (cancer).

[0163] The term "pharmaceutically acceptable excipient" refers to a diluent, adjuvant, excipient or carrier that is administered with the polymer complex. The pharmaceutical carrier can be a sterile liquid, such as water and oil, including oils of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. When the pharmaceutical composition is administered intravenously, water is a preferred carrier. Saline solutions and aqueous glucose and glycerol solutions can also be used as liquid carriers, particularly for injectable liquids. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, limestone, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerol, propylene glycol, water, ethanol, etc. If necessary, the composition may also contain a small amount of a wetting agent or emulsifier or a pH buffer. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release preparations, etc.

[0164] Example

[0165] The present invention will now be described with reference to specific examples. These examples are exemplary only and are for illustrative purposes only: they are not intended to limit the scope of the monopoly claimed or the invention described in any way. These examples constitute the best mode of practicing the present invention currently contemplated.

[0166] Example 1-Y Polymer (4-branched diamine)

[0167] An embodiment of a 4-branched diamine hyperbranched cationic polymer is prepared using BDA, EDA (or HMDA), S5 and DA (or DATA) monomers according to Scheme 1 below.

[0168] Cationic Y polymers were synthesized using the following monomers: BDA, EDA (or HMDA), S5, and DA (or DATA). Y polymers were copolymerized using commercially available monomers via the "A2+B4+C2" Michael addition strategy. Each selected monomer in the reaction system plays a very critical role in the final Y4 polymer. Diamine monomers (B4) were used as branching units to produce highly branched polymers by combining with linear diacrylate monomers (A2). Further post-synthesis modifications involved capping the polymer end groups with other (amine monomers, C2) to remove any unreacted vinyl groups. The monomers were added to a round-bottom flask with magnetic stirring. The flask was partially immersed in an oil bath and the polymerization reaction was carried out at 90°C. The progress of the polymer synthesis reaction was followed by measuring the molecular weight, conversion, and PDI using gel permeation chromatography (GPC). When the polymer molecular weight (Mw) approached 10-20 kDa, the reaction was stopped by withdrawing from the heat source and diluting with DMSO. Chain termination of the Y polymer was achieved by reacting the polymer solution with an amine end-capping agent at room temperature for 48 hours. After end-capping, the Y polymer was purified by precipitation twice in excess diethyl ether to remove any remaining residual monomers, unreacted end-capping agent and small oligomers. To obtain the final product, the Y polymer was dried in a vacuum oven for 48 hours to remove residual solvent.

[0169] Example 2-P Polymer (4-branched tetraacrylate)

[0170] Embodiments of 4-branched tetraacrylate hyperbranched cationic polymers were prepared using BDA, PTTA (or DTTA), S5 and DA (or DATA) monomers according to Scheme 2 below: P1 polymer (7 kDa) and P2 polymer (10 kDa).

[0171] BDA, PTTA (or DTTA) and S5 were mixed in a flask containing DMSO as solvent. The reaction was carried out at 90°C until the target Mw was reached. The reaction was stopped by removing the heat source of the reaction flask and cooling with ice. The end-capped monomer DA (or DATA) was added to the flask containing DMSO and reacted with the acrylate residue at room temperature for 48 hours. The reaction mixture was then precipitated into excess ether twice to remove monomers and oligomers. Drying in a vacuum oven gave P1 and P2 polymers with Mw of 7 kDa and 10 kDa, respectively.

[0172]

[0173] Solution 1

[0174]

[0175] Solution 2

[0176]

[0177] Solution 3

[0178] Proton NMR ( 1 H-NMR) determination:

[0179] The chemical structures of Y4 and P polymers are shown by 1 H-NMR confirmation. The polymer was dissolved in deuterated chloroform (CDCl3) and measured using a 300 MHz Bruker NMR instrument. All chemical shifts are reported in ppm relative to tetramethylsilane (TMS). Figure 11.

[0180] Molecular weight was determined by gel permeation chromatography (GPC):

[0181] The molecular weight and polydispersity of Y4 polymer and P polymer were determined by GPC. 50 μL of the reaction mixture was collected and diluted into 1 mL of DMF, filtered through a 0.22 μm filter, and analyzed at 60 °C using an Agilent 1260 GPC / SEC instrument equipped with a triple detector. DMF was used as the mobile phase at a flow rate of 1 mL / min. Poly(methyl methacrylate) was used as the standard sample for GPC calibration. Figure 12.

[0182] Synthesis of polyplexes involving polymers and plasmid DNA

[0183] Polyplexes are formed by first preparing an aqueous polymer solution and a DNA solution in a suitable solvent (e.g., 25 mM sodium acetate), mixing the dissolved DNA and dissolved polymer together at a 1:1 v / v ratio, and incubating the polymer-DNA solution at room temperature for 10 minutes to allow the formation of polyplexes before use. The aqueous polyplex solution should be vigorously mixed to ensure a homogeneous solution.

[0184] Cell viability studies

[0185] Quantitative measurement of cell proliferation and metabolic health using alamarBlue TM Assay to evaluate cytotoxicity induced by different polyplex conditions. 48-72 hours after cell transfection, assess cell viability. Remove the culture medium from the cells in the well plate and wash the cells with HBSS (Hanks Balanced Salt Solution) in each well. Then, add 100 μl of alamarBlue TM Working solution (10% alamarBlueTM HBSS solution) was added to each well and incubated in the dark for 2 hours under normal cell culture conditions. TM The solution was transferred to a new flat-bottom 96-well plate and the absorbance at 570 nm and 600 nm was recorded using a SpectraMax M3 multi-mode microplate reader. A background reading of alamarblue alone was subtracted from each sample. TM Untreated cells were used to normalize fluorescence values ​​and plotted as 100% viability.

[0186] Cell transfection studies of polymer-DNA polyplexes

[0187] Cells were seeded 24 to 48 hours before transfection to allow attachment to well plates and flasks. Cells were seeded at an optimized cell density. On the day of transfection, polymer-DNA complexes were prepared and mixed with appropriate cell culture medium after complexation so that the final polymer complex solution did not exceed 20% of the total culture medium volume. Cell culture medium containing polymer-DNA complexes was added to the cells and removed 4 hours later and replaced with fresh culture medium to remove the complexes.

[0188] RNP System

[0189] Both crRNA and tracrRNA were diluted to 100 μM using a nuclease-free double buffer, where HiFi Cas9 nuclease was used at a stock concentration of 62 μM according to the manufacturer's instructions. RNP complexes were prepared so that the sgRNA (crRNA + tracrRNA): Cas9 molar ratio was 1-10: 1. The premix was heated at 95 ° C for 5 minutes in a thermal cycler to anneal crRNA and tracrRNA. They were then removed from the heat source and cooled to room temperature on the bench. HiFi Cas9 nuclease was added to each premix and allowed to complex in the dark for 15 minutes at room temperature. In a manner similar to plasmid DNA-based transfection, polymer: RNP polyplexes (ribose polyplexes) were prepared for transfection. As previously described, the polymer was diluted to the desired concentration in 25 mM sodium acetate buffer. Equal amounts of each RNP premix 1 and 2 were used for each transfection. To calculate the w / w ratio of the polymer, the total weight of the RNP complex was used. To form the complex, the polymer solution was mixed with the RNP solution at a 1:1 v / v ratio. After mixing together by pipetting up and down, the complex was incubated at room temperature for 15 minutes to allow polymer-RNP interaction. Once the incubation is complete, the ribopolyplex solution can be diluted in the appropriate cell culture medium and added to the cells. After 4 hours of transfection, the medium was changed and replaced with fresh medium. The ATTO 550nm fluorophore on the tracrRNA was used as an indicator of transfection efficiency.

[0190] Equivalent

[0191] The foregoing description describes the present preferred embodiment of the present invention in detail. After considering these descriptions, it is expected that many modifications and changes can be made in its practice by those skilled in the art. These modifications and changes are intended to be included in the claims appended hereto.

Claims

1. A four-branched polymer prepared by reacting the following components together: (i) four-branched monomers; (ii) diacrylate component (a) of formula (I) wherein Z2 is a straight or branched carbon chain of 1 to 30 carbon atoms, a straight or branched carbon chain of 1 to 30 atoms containing heteroatoms, a carbocyclic ring containing 3 to 30 carbon atoms, or a heterocyclic ring containing 3 to 30 atoms; wherein Z2 is unsubstituted or substituted by at least one of halogen, hydroxy, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C5 alkyl, carboxyl, cyano, nitro, nitroso, -OC(O)NR'R', -N(R')C(O)NR'R', -N(R')C(O)O-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl; or (b) selected from the following: (iii) a first amine component comprising 3 to 20 atoms, wherein the amine component is unsubstituted or substituted by at least one of halogen, hydroxyl, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C6 alkyl, carboxyl, cyano, nitro, nitroso, -OC(O)NR'R', -N(R')C(O)NR'R', -N(R')C(O)O-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl; and (iv) a second amine component comprising 3 to 20 atoms, wherein the amine component is unsubstituted or substituted by at least one of halogen, hydroxyl, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C6 alkyl, carboxyl, cyano, nitro, nitroso, -OC(O)NR'R', -N(R')C(O)NR'R', -N(R')C(O)O-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl; The diacrylate and the first amine component react together to form a first oligomer, the first oligomer and the second amine component react together to form a second oligomer, and the second oligomer and the tetra-branched monomer react together to form the tetra-branched polymer.

2. The tetra-branched polymer according to claim 1, wherein the diacrylate component (a) include:

3. The tetra-branched polymer of claim 1, wherein the tetra-branched monomer, the diacrylate component, and the first amine component react together in a Michael addition reaction to form a first polymer, and the first polymer and the second amine component react together in a Michael addition reaction to form the tetra-branched polymer.

4. The tetra-branched polymer according to any one of the preceding claims, wherein the tetra-branched monomer is selected from a diamine component, a tetraacrylate component, a tetraacrylamide component, a tetrathiol component, a tetraepoxy component and a tetrasubstituted silane.

5. The tetra-branched polymer of claim 4, wherein the tetra-branched monomer is 4-arm-PEG-acrylate.

6. The tetra-branched polymer of claim 1, wherein the first amine component is selected from:

7. The tetrabranched polymer of claim 1, wherein the second amine component is a amine having the structure NH 2 -L 4 -NH 2 The diamine component is selected from: in, L 4 For the connector.

8. The tetra-branched polymer of claim 1, wherein the second amine component is selected from:

9. A polyplex composition comprising the four-branched polymer according to any one of the preceding claims and a component containing nucleic acid complexed together. 10 . The polyplex composition according to claim 9 , wherein the nucleic acid-containing component is selected from a nucleic acid expression system and a ribonucleoprotein gene editing system. The polyplex composition according to claim 10 , wherein the nucleic acid expression system comprises a plasmid and a minicircle.

12. The polyplex composition of claim 11, wherein the plasmid comprises a nanoplasmid.

13. The polymer complex composition according to claim 9 or 12, wherein the nucleic acid-containing component is a ribonucleoprotein gene editing system. The polymer complex composition according to claim 9 , wherein the particle size of the composition is 100-500 nm.

15. The polyplex composition of claim 9, for use as a medicament.

16. A method of forming a tetra-branched polymer comprising the steps of reacting together: (i) four-branched monomers; (ii) diacrylate component (a) of formula (I) wherein Z2 is a straight or branched carbon chain of 1 to 30 carbon atoms, a straight or branched carbon chain of 1 to 30 atoms containing heteroatoms, a carbocyclic ring containing 3 to 30 carbon atoms, or a heterocyclic ring containing 3 to 30 atoms; wherein Z2 is unsubstituted or substituted by at least one of halogen, hydroxy, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C5 alkyl, carboxyl, cyano, nitro, nitroso, -OC(O)NR'R', -N(R')C(O)NR'R', -N(R')C(O)O-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl; or (b) selected from the following: (iii) a first amine component comprising 3 to 20 atoms, wherein the amine component is unsubstituted or substituted by at least one of halogen, hydroxyl, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C6 alkyl, carboxyl, cyano, nitro, nitroso, -OC(O)NR'R', -N(R')C(O)NR'R', -N(R')C(O)O-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl; and (iv) a second amine component comprising 3 to 20 atoms, wherein the amine component is unsubstituted or substituted by at least one of halogen, hydroxyl, amino, sulfonyl, sulfonamido, thiol, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 ether, C1-C6 thioether, C1-C6 sulfone, C1-C6 sulfoxide, C1-C6 primary amide, C1-C6 secondary amide, halogenated C1-C6 alkyl, carboxyl, cyano, nitro, nitroso, -OC(O)NR'R', -N(R')C(O)NR'R', -N(R')C(O)O-C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 heterocyclyl, C2-C5 heteroaryl and C6-C10 aryl; wherein each R' is independently selected from the group consisting of hydrogen and C1-C6 alkyl; The diacrylate and the first amine component react together to form a first oligomer, the first oligomer and the second amine component react together to form a second oligomer, and the second oligomer and the tetra-branched monomer react together to form the tetra-branched polymer.

17. The method according to claim 16, wherein the diacrylate component (a) include:

18. The method of claim 16, wherein the tetra-branched monomer, the diacrylate component, and the first amine component react together in a Michael addition reaction to form a first polymer, and the first polymer and the second amine component react together in a Michael addition reaction to form the tetra-branched polymer.

19. The method according to any one of claims 16 to 18, wherein the tetra-branched monomer is selected from a diamine component, a tetraacrylate component, a tetraacrylamide component, a tetrathiol component, a tetraepoxy component and a tetrasubstituted silane.

20. The method of claim 19, wherein the tetra-branched monomer is selected from 4-arm-PEG-acrylate.